Login to Your Account



Pharma: Clinic Roundup


Tuesday, October 23, 2012
• Teva Pharmaceutical Industries Ltd., of Jerusalem, presented Phase IIa data for laquinimod in Crohn's disease showing treatment with laquinimod 0.5 mg/day gave a remission rate of 48.3 percent, compared to 15.9 percent for patients receiving placebo.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription